Form 4: ARS Pharmaceuticals Director Peter A. Thompson Sells Shares in Multiple Transactions

Director Peter A. Thompson reports selling shares of ARS Pharmaceuticals (SPRY) across several transactions between August 21 and August 23, 2024.

Summary

• Peter A. Thompson, a director of ARS Pharmaceuticals, sold shares of the company's common stock between August 21 and August 23, 2024.
• On August 21, 2024, he sold 394,400 shares at a weighted average price of $13.52 and 13,300 shares at a weighted average price of $14.61.
• On August 22, 2024, he sold 391,482 shares at a weighted average price of $12.94.
• On August 23, 2024, he sold 69,500 shares at a weighted average price of $13.03.
• Following these transactions, Thompson indirectly owns 544,677 shares through OrbiMed Partners Master Fund Limited, 269,323 shares through OPI VI IP HoldCo LLC, and 8,019,187 shares through OrbiMed Private Investments VI, LP.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the director selling shares, which could indicate a lack of confidence. However, the director still holds a significant number of shares indirectly.

Negatives

• A director selling shares could be interpreted negatively by the market, potentially signaling a lack of confidence in the company's near-term prospects.

Risks

• The market may react negatively to the director's share sales, potentially leading to a decrease in the stock price.
• Continued selling by insiders could further erode investor confidence.

Industry Context

Insider trading activity is closely monitored in the pharmaceutical industry, as it can provide insights into the perceived value and future prospects of a company and its products.

Key Dates